Phillips v. C.R. Bard, Inc.

290 F.R.D. 615, 2013 WL 1333790, 2013 U.S. Dist. LEXIS 45647
CourtDistrict Court, D. Nevada
DecidedMarch 29, 2013
DocketNo. 3:12-cv-00344-RCJ-WGC
StatusPublished
Cited by46 cases

This text of 290 F.R.D. 615 (Phillips v. C.R. Bard, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Phillips v. C.R. Bard, Inc., 290 F.R.D. 615, 2013 WL 1333790, 2013 U.S. Dist. LEXIS 45647 (D. Nev. 2013).

Opinion

ORDER RE BARD’S ASSERTION OF THE ATTORNEY-CLIENT PRIVILEGE AND WORK PRODUCT DOCTRINE AS TO FORTY-THREE JOINT SELECTION DOCUMENTS

WILLIAM G. COBB, United States Magistrate Judge.

In this order, the court will undertake a review of the assertion of the attorney-client privilege and work product doctrine by Defendants C.R. Bard, Inc., and Bard Peripheral Vascular, Inc. (collectively, “Bard”) as to certain documents generated by Bard, the production of which is sought by Plaintiff Kevin Phillips. Additionally, collateral issues associated with Bard’s document production, including the adequacy of Bard’s privilege log and waiver have also been submitted to the court. After multiple hearings and extensive briefing on the issues attendant to Bard’s assertion of the attorney-client privi[623]*623lege and work product doctrine, the court issues the instant Order.

I. BACKGROUND OF LITIGATION

This product liability action arises from the alleged failure of a medical device called the “Recovery Filter System” (“Recovery Filter”) manufactured by Bard. The Recovery Filter is a vena cava filter designed to be surgically implanted to prevent pulmonary embolisms from reaching the patient’s lungs. Plaintiff avers he underwent surgical implantation of the Recovery Filter in August 2005. According to Plaintiff, the Recovery Filter subsequently failed and migrated to his heart, causing him to undergo extensive medical treatment and care, including emergency open heart surgery on April 30, 2010.

Plaintiff alleges that the Recovery Filter is defectively designed because it has much higher rates of migration and fracture and associated injuries, including fatalities, than does Bard’s predecessor device and/or other comparable filters. Plaintiff further claims that Bard failed to establish and maintain minimum industry safety standards to ensure that the Recovery Filter was designed to be reasonably safe when used in an intended and reasonably foreseeable manner. Plaintiff contends Bard failed to meet minimum industry safety standards regarding establishing and maintaining a post-market surveillance system to investigate and track and trend reported adverse events, and failed to take timely and reasonable corrective and/or preventative action once the unreasonably dangerous nature of the Recovery Filter was discovered or should have been discovered.

Lastly, Plaintiff claims that Bard was aware of the alleged design defect in the Recovery Filter in advance of August 2005, when Plaintiff underwent implantation of the device. Plaintiff avers that Bard has never adequately warned of and has made material misrepresentations to consumers regarding the risks associated with the intended and reasonable use of the Recovery Filter.

Bard introduced the Recovery Filter into the market in late 2002 after it was cleared by the United States Food and Drug Administration (“FDA”). As a defense, Bard contends the risks of fracture, migration, perforation, and tilt are known and well-documented risks with not only its but all inferior vena cava (IVC) filters. Bard cites statistics that filter migration has been reported in eighteen percent of patients who receive IVC filters and that the occurrences of migration with its Recovery Filter are below that percentage. Bard argues that despite the acknowledged risk of complications with IVC filters, most physicians agree that the benefits outweigh the risks inherent in the device because IVC filters provide critical protection against potentially life-threatening pulmonary emboli and related clotting problems.

Bard further asserts that simply because a filter migrates or fractures does not mean it is defective. Finally, Bard contends that Plaintiffs claims are barred, in whole or in part, by the application of Comment K to Restatement (Second) of Torts § 401A.

II. CASE MANAGEMENT: Discovery and Bard’s Assertion of Attorney-Client Privilege and Work Product Doctrine

Numerous case management status reports have been filed, conferences held, and orders entered up to this point in this litigation. (See, e.g., Docs. ## 31, 32, 36, 46, 48, 68 and 77.) The issue of the assertion of attorney-client privilege and work product doctrine relative to Bard’s document production was first brought to the court’s attention in the parties’ Joint Case Management Report. (Doc. #31 at 32-33.) At that time, the parties noted that several other similar Recovery Filter cases are pending throughout the United States, including one where Bard has produced over two million pages of documents. (Id. at 10-14). Bard has reduplicated its document productions in this litigation (and also responses to Plaintiffs request for production of documents) from a predecessor case. As relevant to this Order, Bard’s production in this matter includes multiple privilege logs which extend over 500 pages with claims of attorney-client privilege or work product doctrine being asserted as to approximately 6800 documents. (See Dec. [624]*62412, 2012 Joint Case Management Report, Doe. # 36 at 5-9.)1

Despite the parties’ efforts to resolve their differences, the production of supplemental privilege logs, and numerous status conferences, they requested the court’s guidance on these issues. (See Doc. # 48.) At a status conference on January 17, 2013, the court requested briefing on the issues that remain in dispute and asked the parties to identify categories of documents which generalize the assertions of privilege or protection, and to submit fifty representative documents along with their briefing which illustrate the parties’ contentions and positions. (See Doc. #46.)

In compliance with the court’s request, the parties submitted extensive briefing. (See Does. ## 52, 54, 63, 64.) Unfortunately, the parties could not agree on the relevant categories of documents and submitted separate identification lists. (Doe. # 52, Attachments 1 & 2 (Exhibits A & B).) Nevertheless, Plaintiff provided Bard with his list of fifty representative selections, which appear in Document Number 60.2 The representative documents have been labeled as “Joint Selection” documents. Bard then submitted these fifty documents to the court for its in camera review.3

Next, the court conducted two lengthy status conferences regarding the parties’ multiple discovery disputes. The first conference, conducted on February 22, 2013, was limited to a discussion of ESI issues, which have been resolved and are the subject of an Interim Case Management Order. (See Docs. ## 68, 77.) The second conference, conducted on March 1, 2013, addressed the attorney-client privilege and work product doctrine issues which are the subject of the instant Order. (See Minutes, Doe. #75.)

Although the court announced certain of its conclusions at the conference on March 1, 2013, this Order will address all of the attorney-client privilege and work product doctrine issues now before the court.

III. LEGAL STANDARD

The analysis of Bard’s assertion of attorney-client privilege and work product doctrine as to certain of its documents presents a somewhat daunting task, particularly in light of the large volume of documents to which these assertions have been made.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
290 F.R.D. 615, 2013 WL 1333790, 2013 U.S. Dist. LEXIS 45647, Counsel Stack Legal Research, https://law.counselstack.com/opinion/phillips-v-cr-bard-inc-nvd-2013.